Bioliberty
Developing robotic rehabilitation hardware and software for people recovering from stroke and neurological conditions.
Website: https://www.bioliberty.com/
Cover Block
Public sources
| Field | Detail |
|---|---|
| Company | Bioliberty |
| Tagline | Developing robotic rehabilitation hardware and software for people recovering from stroke and neurological conditions. |
| Headquarters | Edinburgh, United Kingdom [Crunchbase] |
| Founded | 2019 [Crunchbase] |
| Stage | Series A [Crunchbase, April 2025] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Robotics |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Rowan Armstrong, Ross O’Hanlon, Conan Bradley, Shea Quinn [University of Edinburgh / Edinburgh Innovations, 2026; LinkedIn, 2026] |
| Funding label | Series A |
| Total disclosed funding | Approximately $13.5 million, including a March 2026 Series A financing and a November 2026 extension [GlobeNewswire, March 2026; Finsmes, November 2026] |
Links
Public sources
- Website: https://www.bioliberty.com/
- LinkedIn: https://uk.linkedin.com/company/bioliberty
Executive Summary
PUBLIC Bioliberty develops robotic rehabilitation hardware and software for stroke and neurological recovery, and it merits attention now because it closed a Series A that reached $13.5 million by November 2026 while beginning to build visible U.S. clinical and investor ties in post-acute care [Finsmes, November 2026] [GlobeNewswire, March 2026]. The company traces its roots to the University of Edinburgh’s School of Engineering, although public sources diverge on whether the founding date is 2019 or 2020; the stronger common thread is that Rowan Armstrong and Ross O'Hanlon were University of Edinburgh engineering graduates who helped spin the business out of that ecosystem [University of Edinburgh / Edinburgh Innovations, 2026] [Edinburgh Innovations, 2026].
The product thesis is relatively clear from the public record: Lifehub Clinic centers on upper-extremity rehabilitation through Lifeglov, a soft robotic glove that uses air-powered assistance to help open the hand, paired with software for therapy delivery and monitoring [National Law Review] [HIT Consultant, May 2025]. That combination matters because Bioliberty is not presenting as a standalone device vendor; according to company financing materials and partner references, it is trying to sell a clinic workflow that blends hardware, software, and care-coordination features for inpatient and outpatient rehabilitation settings [GlobeNewswire, March 2026] [Sheltering Arms Institute, 2026] [Bioliberty].
The team reads as technically grounded and institutionally linked, with Armstrong publicly identified as co-founder and CEO, and additional co-founders including Ross O'Hanlon, Conan Bradley, and Shea Quinn in University and founder-linked materials [Sheltering Arms Institute, 2026] [University of Edinburgh / Edinburgh Innovations, 2026] [LinkedIn, 2026]. Public evidence is thinner on prior scaled commercial operating history, so the near-term case rests more on product-market validation inside rehabilitation networks than on a long record of repeat company building [University of Edinburgh / Edinburgh Innovations, 2026] [LinkedIn].
On capital formation, the picture is straightforward even if currency reporting varies by source. Bioliberty announced $10.2 million in March 2026, including participation from the Scottish National Investment Bank, Archangels, Eos Advisory, Old College Capital, Hanna Capital SEZC, and Conduit Connect, then added a $3.3 million extension in November 2026 from TGH Ventures, Ballad Ventures, 25M Health, and Whiterock, bringing the disclosed Series A total to $13.5 million [GlobeNewswire, March 2026] [Finsmes, November 2026] [Scottish National Investment Bank, 2026].
The business model appears to be provider-facing healthtech, selling into rehabilitation hospitals and post-acute care systems rather than direct-to-consumer channels, with public references to deployments or partnerships that include Sheltering Arms Institute and several large U.S. post-acute providers [Sheltering Arms Institute, 2026] [GlobeNewswire, March 2026]. Over the next 12 to 18 months, the central watchpoints are whether those early clinical relationships convert into repeatable commercial adoption, whether U.S. rollout and manufacturing scale without execution slippage, and whether Bioliberty can prove that its combined hardware-software approach improves therapy throughput or outcomes strongly enough to support enterprise buying behavior [Finsmes, November 2026] [GlobeNewswire, March 2026].
Lightly corroborated -- Relies on company announcement channels and university-linked materials, with partial corroboration from Finsmes, Sheltering Arms Institute, and the Scottish National Investment Bank.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Robotics |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Total disclosed approximately $13,500,000 |
How the Company Got Here
PUBLIC Bioliberty is an Edinburgh-based rehabilitation technology company focused on neurological recovery, with company materials describing a platform built around robotic therapy tools and software for stroke and related conditions [Bioliberty]. Crunchbase lists the company as headquartered in Edinburgh, United Kingdom, and founded in 2019 [Crunchbase]. The public record on founding date is not fully aligned, but the higher-confidence company profile points to 2019 rather than later secondary references [Crunchbase].
The more useful point for investors is the institutional origin. Bioliberty traces back to the University of Edinburgh ecosystem through its engineering roots, and its public company profile presents a clinically oriented rehabilitation mission rather than a broad consumer-health pitch [Bioliberty]. That matters because the company appears to have been built for provider workflows from the outset, which is consistent with a longer commercialization cycle but also a clearer reimbursement and deployment context [Bioliberty].
A short chronology is visible from public profiles. Crunchbase records Bioliberty's formation in 2019 and identifies the business as an active venture-backed company in medical technology [Crunchbase]. The company website now presents a named rehabilitation platform and active commercial presence, indicating that the business has moved beyond concept stage into go-to-market execution, even if the website does not provide a full milestone timeline in one place [Bioliberty].
Lightly corroborated -- Confirmed primarily by Crunchbase and the company website, with partial corroboration but limited date precision in company-controlled materials.
Product and Technology
MIXED
Bioliberty is building a clinic-focused rehabilitation system around upper-limb recovery, and the public record is reasonably consistent on the product shape even where feature detail is still thin. The company and third-party coverage describe Lifehub Clinic as the core platform, combining the Lifeglov soft robotic glove with software intended to support therapy delivery for people recovering from stroke and other neurological conditions [Bioliberty] [National Law Review] [HIT Consultant, May 2025]. Sheltering Arms Institute states that Bioliberty developed Lifehub Clinic in collaboration with leading physical rehabilitation centers, which matters because it suggests the product has been shaped around provider workflow rather than consumer wellness use cases [Sheltering Arms Institute, 2026].
The hardware claim is more concrete than the software claim. HIT Consultant describes Lifeglov as an air-powered soft robotic glove that provides controlled assistance to open the hand and can be calibrated to a patient's functional ability [HIT Consultant, May 2025]. GlobeNewswire's March 2026 financing announcement adds that the broader system is being built for post-acute care and references planned computer-vision and care-coordination capabilities, but those should be read as announced product direction rather than fully evidenced live functionality from independent testing [GlobeNewswire, March 2026].
The software stack is only partly visible from public evidence, so the safest reading is that Bioliberty pairs assistive hardware with therapist-facing software and patient monitoring, while keeping the exact technical architecture opaque. The company website describes Lifehub as the central control unit for its soft robotic wearables [Bioliberty], and a surfaced Software Engineer (Unity) role points to Unity usage in the product environment (inferred from job postings) [LinkedIn, Unknown]. Public materials also point to a U.S. market launch in May 2025 and deployments with rehabilitation providers, but they do not establish detailed data integrations, reimbursement workflow, or the extent of autonomous AI decision-making in clinical use [GlobeNewswire, March 2026] [Sheltering Arms Institute, 2026] [LinkedIn, Unknown].
Lightly corroborated -- Product form factor is corroborated across the company website, provider coverage, and trade press, but several software-capability details rely on company-linked announcements or job-posting inference.
Where the Demand Sits
Public sources
Neurological rehabilitation is one of those healthcare markets where the demand signal is easier to see than the budget line, because rising stroke prevalence, clinician shortages, and pressure to move therapy beyond the acute setting all point in the same direction, while product-specific market sizing remains patchy in public sources [HIT Consultant, May 2025] [MassDevice] [GlobeNewswire, March 2026].
Bioliberty sits at the intersection of several adjacent markets rather than inside one neatly reported category. The company is building upper-limb rehabilitation hardware and software for stroke and neurological recovery, with its Lifehub Clinic system centered on a soft robotic glove and clinic software [National Law Review] [HIT Consultant, May 2025] [Bioliberty]. Public sources provided for this report do not include a named third-party TAM, SAM, or SOM for Bioliberty's exact category, so the cleaner approach is to anchor on analogous markets: neurorehabilitation, post-acute rehabilitation technology, and robotic rehabilitation devices. That framing matters because buyers are likely to compare a product like Lifehub Clinic not only against robotic therapy systems, but also against conventional occupational therapy workflows, digital rehab tools, and home exercise compliance programs [GlobeNewswire, March 2026] [Sheltering Arms Institute, 2026].
The demand drivers in the public record are mostly clinical workflow and care-delivery drivers, not consumer wellness trends. Bioliberty's March 2026 financing announcement says the company is building "functional intelligence capabilities for post-acute care," and ties the product to patient monitoring, care coordination, and computer-vision-assisted rehabilitation workflows [GlobeNewswire, March 2026]. Third-party coverage also describes the Lifeglov device as air-powered hand-opening assistance calibrated to each patient's functional ability, which points to a market need around therapist productivity and more consistent dose delivery in upper-extremity rehab [HIT Consultant, May 2025]. Sheltering Arms Institute's description of collaboration with rehabilitation centers suggests providers are looking for tools that fit existing inpatient and outpatient care models rather than requiring a fully new care setting [Sheltering Arms Institute, 2026].
The adjacent markets are important because they widen the budget path if the core robotic glove category proves too narrow. A hospital or rehab network could evaluate Bioliberty as a capital device, as a therapy-enablement software layer, or as part of a broader post-acute care modernization effort, particularly if care coordination and monitoring features mature beyond the wearable itself [GlobeNewswire, March 2026] [Bioliberty]. The substitute set is therefore broad: standard therapist-led upper-limb rehab, lower-cost nonrobotic assistive tools, and software-only neurorehabilitation programs all compete for the same departmental budget, even when they do not match the same mechanism of action [HIT Consultant, May 2025] [MassDevice].
Regulatory and macro forces look supportive in direction, though the public evidence here is more qualitative than numeric. The company's commercial emphasis on U.S. post-acute care providers reflects a market where providers are under pressure to show functional outcomes and manage staffing constraints across inpatient rehabilitation, outpatient follow-up, and longer recovery windows [GlobeNewswire, March 2026] [Daytraders.com, March 2026]. At the same time, hardware adoption in clinical settings usually faces slower procurement cycles, training requirements, and reimbursement ambiguity compared with software-only tools. That does not negate the opportunity, but it does mean market adoption is likely to track proof of workflow fit and outcomes evidence more than category excitement alone [Sheltering Arms Institute, 2026] [Finsmes, November 2026].
| Market lens | What public sources support | Source quality |
|---|---|---|
| Core market | Upper-limb neurological rehabilitation hardware and software, centered on stroke and related conditions | Company and third-party corroboration [Bioliberty] [National Law Review] [HIT Consultant, May 2025] |
| Care setting | Inpatient and outpatient rehabilitation, with post-acute care emphasis | Third-party and company-linked sources [GlobeNewswire, March 2026] [Sheltering Arms Institute, 2026] |
| Buyer set | Healthcare providers and rehabilitation networks rather than direct-to-consumer channels | Company-linked and third-party corroboration [Bioliberty] [GlobeNewswire, March 2026] |
| Adjacent budgets | Care coordination, patient monitoring, and rehabilitation workflow software | Primarily company-announcement based, partially echoed in coverage [GlobeNewswire, March 2026] [MassDevice] |
| Geographic commercialization focus | U.S. provider market expansion and deployments | Third-party and announcement coverage [Finsmes, November 2026] [GlobeNewswire, March 2026] |
The table makes the constraint plain: the addressable market case is credible at the category level, but the public file is stronger on buyer need and workflow relevance than on third-party market size quantification. For investors, that shifts diligence toward procurement dynamics, reimbursement pathway, and measured therapy outcomes rather than headline TAM arithmetic.
Lightly corroborated -- Market characterization is supported by company materials and third-party coverage, but no named third-party TAM/SAM/SOM dataset was provided in the source set, and several market-adjacent claims rely on company-announcement framing corroborated only in part by external coverage.
Competitive Landscape
MIXED Bioliberty appears to sit in a narrower lane than broad rehabilitation software vendors, with its positioning anchored in clinic-based upper-limb neurorehabilitation hardware paired with software rather than software alone [Bioliberty] [National Law Review] [HIT Consultant, May 2025].
The public record here is thinner than an investor would want, because the available source set does not name direct competitors for a like-for-like comparison. Even so, the competitive map is still legible in segments. At one end are incumbent rehabilitation providers and therapy-equipment vendors that already control clinician relationships and procurement budgets, which matters because Bioliberty sells into providers rather than consumers [Bioliberty]. At the other are adjacent substitutes, including standard upper-limb occupational-therapy workflows and nonrobotic therapy tools, which remain the default alternative whenever a clinic decides the added hardware, training, or reimbursement complexity is not justified by outcomes or throughput improvements. That leaves Bioliberty competing less on novelty and more on whether a soft-robotic glove plus software can fit inside existing post-acute care operations without adding too much friction [GlobeNewswire, March 2026] [Sheltering Arms Institute, 2026].
The edge that is visible in public sources is distributional rather than purely technical. Bioliberty says its technology supports patients at several large U.S. post-acute care providers, has a multicenter partnership with the third-largest rehabilitation provider in the country, and is deployed with Sheltering Arms Institute [GlobeNewswire, March 2026] [Daytraders.com, March 2026] [Sheltering Arms Institute, 2026]. The November 2026 extension also brought in TGH Ventures, Ballad Ventures, 25M Health, and Whiterock, which suggests the company is adding healthcare-connected capital while pushing U.S. commercialization [Finsmes, November 2026]. That edge could compound if these relationships convert into repeat site deployments and proprietary rehabilitation data, but it is still perishable because the public sources do not establish site counts, contract duration, unit economics, or evidence that these partnerships are exclusive.
The clearest exposure is channel dependence. Bioliberty does not appear, from the public record, to own a direct patient channel, and its current wedge is tied to institutional adoption in inpatient and outpatient settings [Bioliberty] [ZEROTH SOURCE]. That means any better-capitalized rehabilitation incumbent with an established sales force, or any clinic network that prefers lower-complexity therapy tools, can slow adoption without needing to match the product feature for feature. There is also a scope constraint in the current positioning: the cited materials point to an initial focus on upper-extremity therapy through Lifeglov, which is a useful beachhead but also narrows the immediate addressable workflow relative to broader neurorehabilitation platforms [National Law Review] [HIT Consultant, May 2025].
The most plausible 18-month scenario is a race between proof of clinical integration and the inertia of existing care pathways. Bioliberty is the likely winner if its current U.S. provider relationships turn into multisite standardization and if the company can show that Lifehub Clinic improves therapist efficiency or patient adherence in routine care, not only in pilot environments [GlobeNewswire, March 2026] [Finsmes, November 2026]. Bioliberty is the likely loser if provider budgets tighten or if procurement committees continue to treat soft-robotic rehabilitation as an optional add-on rather than a core workflow, because the company's present advantage appears to rest on early access and clinical collaboration rather than on an already dominant installed base [Sheltering Arms Institute, 2026] [University of Edinburgh / Edinburgh Innovations, 2026].
Opportunity
Upside case
PUBLIC The prize here is not a better rehab device in a niche clinic, but a shot at becoming a standard operating layer for upper-limb neurorehabilitation across large post-acute care systems in the U.S. and, over time, beyond them.
The headline opportunity is straightforward. If Bioliberty can turn Lifehub Clinic from a single soft-robotic glove system into the workflow that providers use to deliver, monitor, and coordinate neurological rehabilitation, it could occupy a more durable position than a hardware vendor usually does [GlobeNewswire, March 2026] [HIT Consultant, May 2025] [National Law Review]. That outcome is reachable, not merely aspirational, because the public record already shows three ingredients that matter: a defined clinical wedge in upper-extremity therapy through Lifeglov [National Law Review] [HIT Consultant, May 2025]; named evidence of collaboration with rehabilitation centers, including Sheltering Arms Institute [Sheltering Arms Institute, 2026]; and early access to large U.S. provider environments, with the company stating that it supports patients at several of the largest post-acute care providers in the U.S. and has a multicenter partnership with the third-largest rehabilitation provider in the country [GlobeNewswire, March 2026]. Add a $13.5 million Series A completed through a November 2026 extension, with backing from both Scottish and U.S. healthcare investors, and the commercial setup is more substantial than a typical early clinical-device rollout [Finsmes, November 2026] [GlobeNewswire, March 2026].
The range of outcomes is still wide, but the public evidence supports several concrete paths to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Post-acute network standard | Bioliberty becomes a preferred neurorehab platform across multi-site rehabilitation and post-acute providers, starting with upper-limb therapy and expanding across sites within each network. | A successful multicenter rollout with large U.S. rehabilitation groups already referenced in company-backed financing coverage [GlobeNewswire, March 2026]. | The company says it already supports patients at several large U.S. post-acute providers and has a multicenter partnership with the third-largest rehabilitation provider in the U.S., which suggests a land-and-expand motion is at least underway [GlobeNewswire, March 2026]. |
| Clinical workflow platform | Lifehub Clinic evolves from device-plus-software into a care coordination and monitoring layer for neurological rehab programs, making switching costs higher than for a standalone glove. | Delivery of the computer-vision, patient-monitoring, and care-coordination capabilities described in the March 2026 financing announcement [GlobeNewswire, March 2026]. | Public materials describe Lifehub as the central unit powering Bioliberty's soft-robotic wearables, while third-party coverage points to an AI-enabled rehabilitation platform rather than a single-purpose device [Bioliberty] [GlobeNewswire, March 2026]. |
| U.S. strategic channel expansion | U.S. health-system and venture relationships turn into reference customers, procurement use, and broader commercialization infrastructure. | The November 2026 extension added TGH Ventures, Ballad Ventures, 25M Health, and Whiterock, with proceeds earmarked for U.S. commercialization, clinical trials, hiring, and manufacturing [Finsmes, November 2026]. | TGH Ventures' participation matters because Tampa General Hospital is described in the source set as a clinical site, creating a plausible bridge between deployment, validation, and distribution support [Finsmes, November 2026]. |
What compounding would look like is less about consumer-style network effects and more about clinical and operational lock-in. A provider that adopts Lifehub Clinic is not only buying a glove. It is adopting therapy protocols, patient monitoring, software interfaces, and, if the company executes on its March 2026 roadmap, computer-vision and care-coordination capabilities that sit closer to the rehab workflow itself [GlobeNewswire, March 2026] [HIT Consultant, May 2025]. In that model, every additional site can improve selling efficiency through referenceability inside the same health system, while every therapy session can add to the company's understanding of patient response patterns for upper-limb rehabilitation. The public record does not yet prove a data moat, but it does show the beginnings of one: collaboration with rehabilitation centers in product development, deployment with named clinical partners, and a software layer intended to monitor patients and support individualized treatment [Sheltering Arms Institute, 2026] [MassDevice] [Bioliberty].
The size of the win is easiest to frame through scenario logic rather than a hard market model, because no credible public market-size figure was provided in the source set. If the "clinical workflow platform" scenario plays out, Bioliberty could plausibly become a strategic acquisition target for a larger rehabilitation, medtech, or care-delivery software player seeking an installed base in neurorecovery and post-acute care, particularly if its provider relationships deepen and the software layer proves sticky [GlobeNewswire, March 2026] [Finsmes, November 2026]. If the "post-acute network standard" scenario plays out, the upside is that the company is valued more like a hybrid medtech-software platform than a single-product device company (scenario, not a forecast). The evidence in hand does not justify a precise valuation range, but it does justify taking the upside seriously: Bioliberty has moved beyond laboratory-stage storytelling into funded U.S. market entry, named clinical relationships, and a product architecture that can expand from hardware assistance into ongoing rehabilitation intelligence [University of Edinburgh / Edinburgh Innovations, 2026] [GlobeNewswire, March 2026] [Finsmes, November 2026].
Lightly corroborated -- This section relies on company-backed financing announcements and university or partner materials, with partial corroboration from Finsmes, GlobeNewswire, Sheltering Arms Institute, and Bioliberty's public site.
Sources
Public sources
[Crunchbase] Bioliberty | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/bioliberty
[University of Edinburgh / Edinburgh Innovations, 2026] Bioliberty secures £7.7m to accelerate product development and international growth | https://eng.ed.ac.uk/about/news/20260323/bioliberty-secures-ps77m-to-accelerate-product-development-and-international
[LinkedIn, 2026] Hugh Carter | Bioliberty | LinkedIn | https://www.linkedin.com/in/hughcolincarter/
[GlobeNewswire, March 2026] Bioliberty Raises $10.2 million to Build Functional Intelligence Capabilities for Post-Acute Care | https://www.globenewswire.com/news-release/2026/03/19/3258693/0/en/bioliberty-raises-10-2-million-to-build-functional-intelligence-capabilities-for-post-acute-care.html
[Finsmes, November 2026] Bioliberty Raises Additional $3.3M in Series A Funding | https://www.finsmes.com/2026/11/bioliberty-raises-additional-3-3m-in-series-a-funding.html
[Scottish National Investment Bank, 2026] Healthtech firm Bioliberty to accelerate international growth with new investment | Scottish National Investment Bank | https://www.thebank.scot/healthtech-firm-bioliberty-to-accelerate-international-growth-with-new-investment
[National Law Review] Bioliberty Raises $10.2 million to Build Functional Intelligence Capabilities for Post-Acute Care | https://www.natlawreview.com/article/bioliberty-raises-102-million-build-functional-intelligence-capabilities-post-acute
[HIT Consultant, May 2025] Bioliberty Launches Lifehub Clinic in the U.S. to Expand Access to Stroke Rehabilitation | https://hitconsultant.net/2025/05/13/bioliberty-launches-lifehub-clinic-in-the-u-s-to-expand-access-to-stroke-rehabilitation/
[Sheltering Arms Institute, 2026] Bioliberty Lifehub Clinic Archives | Sheltering Arms Institute | https://shelteringarmsinstitute.com/tag/bioliberty-lifehub-clinic/
[Bioliberty] Bioliberty | Rehabilitation Technology for Neurological Recovery | https://www.bioliberty.com/
[Edinburgh Innovations, 2026] Edinburgh Innovations | Bioliberty receives £2.2M for soft robotic glove to help stroke recovery | https://edinburgh-innovations.ed.ac.uk/news/startup-receives-2-2m-for-soft-robotic-glove-to-help-stroke-recovery
[Pulse2, 2026] Bioliberty: $10.2 Million Raised For Functional Intelligence Platform In Post-Acute Care | https://pulse2.com/bioliberty-10-2-million-raised-for-functional-intelligence-platform-in-post-acute-care/amp/
[MassDevice] Bioliberty launches Lifehub Clinic to expand access to stroke rehab in U.S. | https://www.massdevice.com/bioliberty-launches-lifehub-clinic-expand-access-stroke-rehab-us/
[Daytraders.com, March 2026] Bioliberty Raises $10.2M to Advance AI-Powered Stroke Rehab Platform | https://www.daytrading.com/news/bioliberty-raises-10-2m-to-advance-ai-powered-stroke-rehab-platform
[LinkedIn] Bioliberty | LinkedIn | https://uk.linkedin.com/company/bioliberty
Articles about Bioliberty
- Bioliberty's Soft Robotic Glove Is Reaching Stroke Patients in U.S. Rehab Networks — The Scottish medtech company, backed by a national investment bank, is deploying its AI-enabled platform in major American rehabilitation centers.